Gemcitabine plus docetaxel (GD) versus capecitabine plus docetaxel (CD) for anthracycline-pretreated metastatic breast cancer (MBC) patients (pts): Results of a European phase III study.

被引：0

作者：

Chan, S

Romieu, G

Huober, J

Delozier, T

Tubiana-Hulin, M

Lluch, A

Schneeweiss, A

Llombart, A

Carrasco, E

Fumoleau, P

机构：

[1] City Hosp Nottingham, Nottingham, England

[2] Ctr Val Aurelle, Montpellier, France

[3] Univ Tubingen, Tubingen, Germany

[4] Ctr Francois Baclesse, F-14021 Caen, France

[5] Ctr Rene Huguenin, St Cloud, France

[6] Hosp Clin Univ, Valencia, Spain

[7] Univ Heidelberg, Heidelberg, Germany

[8] Inst Valencia Oncol, Valencia, Spain

[9] Eli Lilly & Co, Alcobendas, Spain

[10] Ctr Georges Francois Leclerc, Dijon, France

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：24S / 24S

页数：1

共 50 条

[41] Phase I/II study of ixabepilone plus capecitabine in anthracycline-pretreated/resistant and taxane-resistant metastatic breast cancer
Bunnell, Craig
Vahdat, Linda
Schwartzberg, Lee
Gralow, Julie
Klimovsky, Judith
Poulart, Valerie
Peck, Ronald
Thomas, Eva
CLINICAL BREAST CANCER, 2008, 8 (03) : 234 - 241
[42] Phase II study of irinotecan plus capecitabine in patients with anthracycline and taxane pretreated metastatic breast cancer
Lee, K. S.
Ro, J.
Park, I. H.
Kim, E. A.
Nam, B.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[43] A phase II study of weekly docetaxel in patients with anthracycline pretreated metastatic breast cancer
Hugo E. R. Ford
Yoon-Sim Yap
David W. Miles
Andreas Makris
Marcia Hall
Liz Miller
Mark Harries
Ian E. Smith
Stephen R. D. Johnston
Cancer Chemotherapy and Pharmacology, 2006, 58 : 809 - 815
[44] A phase II study of weekly docetaxel in patients with anthracycline pretreated metastatic breast cancer
Ford, Hugo E. R.
Yap, Yoon-Sim
Miles, David W.
Makris, Andreas
Hall, Marcia
Miller, Liz
Harries, Mark
Smith, Ian E.
Johnston, Stephen R. D.
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2006, 58 (06) : 809 - 815
[45] A multicentre phase II study to evaluate sequential docetaxel followed by capecitabine treatment in anthracycline-pretreated HER-2-negative patients with metastatic breast cancer
Bayo, Juan
Lomas, Maria
Salvador, Javier
Moreno, Alberto
Ruiz, Manuel
Rodriguez, Alberto
Fuentes, Jose
Fernandez-Freire, Ana
Bernabe, Reyes
Fernandez, Andrea
CLINICAL & TRANSLATIONAL ONCOLOGY, 2008, 10 (12): : 817 - 825
[46] Weekly Paclitaxel plus Capecitabine versus Docetaxel Every 3 Weeks plus Capecitabine in Metastatic Breast Cancer
Wist, E. A.
Mjaaland, I.
Lokkevik, E.
Sommer, H. H.
JOURNAL OF ONCOLOGY, 2012, 2012
[47] A pilot study of weekly versus 3-week docetaxel in combination with capecitabine in patients with anthracycline-pretreated metastatic breast cancer (CHN-TAX 614)
Jiang, Z.
Zhang, S.
Song, S.
Ren, J.
Jiao, S.
Liu, D.
Sun, Q.
Wang, H.
Xie, X.
Liu, J.
EJC SUPPLEMENTS, 2005, 3 (02): : 122 - 123
[48] Preliminary results of Capecitabine (C) associated with Vinorelbine (V) in taxane and anthracycline-pretreated metastatic breast cancer (MBC)
Estevez, L. G.
Batista, N.
Sanchez-Rovira, P.
Velasco, A.
Domine, M.
Lobo, F.
Oramas, J.
Cruz, J.
ANNALS OF ONCOLOGY, 2004, 15 : 44 - 44
[49] Population-based pharmacoeconomic model for adopting capecitabine/docetaxel combination treatment for anthracycline-pretreated metastatic breast cancer
Verma, S
Ilersich, AL
ONCOLOGIST, 2003, 8 (03): : 232 - 240
[50] A multicentre phase II study to evaluate sequential docetaxel followed by capecitabine treatment in anthracycline-pretreated HER-2-negative patients with metastatic breast cancer
Juan Bayo
María Lomas
Javier Salvador
Alberto Moreno
Manuel Ruiz
Alberto Rodríguez
José Fuentes
Ana Fernández-Freire
Reyes Bernabé
Andrea Fernández
Clinical and Translational Oncology, 2008, 10

← 1 2 3 4 5 →